AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02242799
Drug: Dolutegravir 50mg od
RxNorm normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir 50mg once daily will be given either alone or in combination, as specified
Trial: NCT02242799
Drug: Artesunate-amodiaquine
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
Trial: NCT02798913
Drug: Short DAPT
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
DrugBank: Ragweed pollen extract (DB05368)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
Trial: NCT01086332
Drug: Nelfinavir
RxNorm normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1250 mg twice daily
Trial: NCT01086332
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
Trial: NCT00221702
Drug: PegIntron
RxNorm normalized name: PegIntron
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mcg SC/week for 36 months
Trial: NCT00221702
Drug: intron A
RxNorm normalized name: Intron A
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3mui TIWW SC for 18 months
Trial: NCT01650727
Drug: Dinaciclib
RxNorm normalized name: Dinaciclib
DrugBank: Dinaciclib (DB12021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m\^2 up to a maximum dose of 14 mg/m\^2.
Trial: NCT03405441
Drug: JNJ-55375515
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-55375515 as per the assigned treatment in Part 2.
Trial: NCT03882996
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe 10 mg daily in the morning
Trial: NCT03882996
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg daily in the morning. Atorvastatin dose could be titrated up (by doubling the dose up to a maximum of 80 mg daily) to achieve the target low-density-lipoprotein cholesterol (LDL-C) level of 100 mg/dL (2.59 mmol/L) after a minimum of 4 weeks of treatment.
Trial: NCT03386214
Drug: Pevonedistat
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a \> 5% change in body weight from the weight used for the most recent BSA calculation.
Trial: NCT03386214
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -Standard of care outside of protocol
Trial: NCT04553042
Drug: Seltorexant
RxNorm normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seltorexant will be administered orally as per assigned treatment sequence.
Trial: NCT03690921
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00570921
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus tablets, two-5 mg tablets a day
Trial: NCT00570921
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
Trial: NCT02945007
Drug: JNJ-53718678
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-53718678 under fed or fasted conditions.
Trial: NCT00219869
Drug: Galantamine
RxNorm normalized name: Galantamine
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03772041
Drug: OPC-61815
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
Trial: NCT03772041
Drug: Tolvaptan Tab 15 MG
RxNorm normalized name: tolvaptan Oral Tablet
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
Trial: NCT02183350
Drug: BI 1356 BS - single rising dose
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00210964
Drug: ceftobiprole plus placebo
DrugBank: Ceftobiprole (DB04918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
Trial: NCT00210964
Drug: linezolid plus ceftazidime
RxNorm normalized name: Linezolid
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
Trial: NCT00231452
Drug: Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
Trial: NCT02795819
Drug: AR-42
RxNorm normalized name: AR-42
DrugBank: AR-42 (DB12707)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-42 tablets were taken orally once per day on 3 non-consecutive days during the first 3 weeks of each 4-week cycle. If treatment was interrupted during the cycle, the cycle was to be extended
Trial: NCT02795819
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pazopanib tablets were taken orally once daily continuously during each 4-week treatment cycle. There were no scheduled breaks in pazopanib therapy
Trial: NCT02228135
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03781947
Drug: teverelix TFA
RxNorm normalized name: Teverelix
DrugBank: Teverelix (DB05624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single s.c. or i.m. injection of teverelix TFA administered on Day 1
Trial: NCT02737202
Drug: saracatinib
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.
Trial: NCT00153023
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00153023
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00607256
Drug: [S,S]-reboxetine
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S_S reboxetine dosed daily.
Trial: NCT00735462
Drug: 2.5% imiquimod cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
Trial: NCT00735462
Drug: 3.75% imiquimod cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
Trial: NCT03140449
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24).
Trial: NCT03140449
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24).
Trial: NCT03140449
Drug: Rapamycin-calcitriol combination
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24).
Trial: NCT00945763
Drug: N1539
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30 mg
Trial: NCT00945763
Drug: N1539
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg
Trial: NCT00945763
Drug: N1539
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60 mg
Trial: NCT00945763
Drug: Motrin
RxNorm normalized name: Motrin
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg
Trial: NCT03389451
Drug: Ga-68 PSMA-HBED-CC PET
RxNorm normalized name: Psma-hbed-CC Ga-68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
Trial: NCT00349388
Drug: Asacol
RxNorm normalized name: Asacol
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asacol is given once a day versus twice or three times a day
Trial: NCT04701528
Drug: Voclosporin
RxNorm normalized name: Voclosporin
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Temporarily switching of tacrolimus maintenance immunosuppression to voclosporin maintenance immunosuppression with possible additional anti-viral activity
Trial: NCT04701528
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT00203723
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02943993
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prescribed according to approved label
Trial: NCT03268603
Drug: Autologous Adipose-derived Mesenchymal Stromal Cells
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Autologous adipose derived mesenchymal stromal cells (DB17925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.
Trial: NCT00510263
Drug: Valaciclovir + placebo
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.
Trial: NCT00510263
Drug: Prednisolone + valaciclovir
RxNorm normalized name: Prednisolone
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.
Trial: NCT04494243
Drug: AD-214 10/600mg
DrugBank: AD-214 (DB18412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet administered before the breakfast during 7 days
Trial: NCT04494243
Drug: Rabeprazole 10mg
RxNorm normalized name: rabeprazole sodium 10 MG
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet administered before the breakfast during 7 days
Trial: NCT04284722
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Perioperative continuation of oral metformin therapy according to the patient's normal dosage and dosage intervals
Trial: NCT00176969
Drug: Capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00162058
Drug: Peflutren Lipid Microsphere Injectable Suspension
RxNorm normalized name: patisiran lipid complex Injection [Onpattro]
DrugBank: Patisiran (DB14582)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00993018
Drug: JNJ-42160443 (1 mg)
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
Trial: NCT00993018
Drug: JNJ-42160443 (3 mg)
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
Trial: NCT00993018
Drug: JNJ-42160443 (10 mg)
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
Trial: NCT01093222
Drug: Erlotinib Hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01093222
Drug: Sorafenib Tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00030745
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00030745
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03746483
Drug: MS1819
RxNorm normalized name: MS1819-SD
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS1819, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
Trial: NCT03746483
Drug: Porcine PERT
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine PERT is being used as a comparator to MS1819 as a second drug/intervention
Trial: NCT00011778
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04362527
Drug: Milrinone 1 Mg/mL Solution for Injection
RxNorm normalized name: Milrinone 1 mg/mL solution for injection
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blinding procedure will be set up for the administration of the treatment
Trial: NCT02893917
Drug: Cediranib
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02893917
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02702739
Drug: Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks
Trial: NCT03284593
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02825719
Drug: Ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal acetate 5mg daily will be prescribed
Trial: NCT02825719
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
Trial: NCT02825719
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
Trial: NCT01580007
Drug: Active Sodium Phenylbutyrate and active cholecalciferol
RxNorm normalized name: Activated Charcoal
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months
Trial: NCT01580007
Drug: Placebo Sodium Phenylbutyrate plus active cholecalciferol
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months
Trial: NCT01580007
Drug: Active Sodium Phenylbutyrate and placebo cholecalciferol
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
Trial: NCT01580007
Drug: Placebo Sodium Phenylbutyrate plus placebo cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
Trial: NCT00375778
Drug: memantine (drug)
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00413634
Drug: anagrelide hydrochloride
RxNorm normalized name: Anagrelide Hydrochloride
DrugBank: Anagrelide (DB00261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
Trial: NCT00413634
Drug: anagrelide hydrochloride
RxNorm normalized name: Anagrelide Hydrochloride
DrugBank: Anagrelide (DB00261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
Trial: NCT00387907
Drug: larotaxel (XRP9881)
RxNorm normalized name: Larotaxel
DrugBank: Larotaxel (DB12984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
Trial: NCT00387907
Drug: trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered as a 90-minute IV infusion on Day 1 of every week (qw)
Trial: NCT03811015
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01196104
Drug: Insulin Aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Usual Care
Trial: NCT01196104
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00610675
Drug: Org 50081
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet daily
Trial: NCT04149262
Drug: Fiasp
RxNorm normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fiasp® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter